Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Cure Can Be Expected Now for Colon Cancer Due to Advances in Pharmacotherapy: Oncologist
July 5, 2017
- Long-Term Safety of PCSK9 Inhibitors Remains to Be Determined: New Atherosclerosis Prevention Guidelines
July 4, 2017
- Japanese Society of Hypertension to Verify Results of SPRINT Study
June 14, 2017
- AbbVie’s Novel Hep C Treatment Achieves 100% SVR in Genotype 1 Hepatitis C Patients with Compensated Cirrhosis
June 13, 2017
- DPP-4 Inhibitor Prevents Deterioration in Cardiac Diastolic Function in Diabetes Patients: Research Sub-Analysis
May 26, 2017
- Will Formularies Spread in Japan? Some Don’t Think So, but MOF Push Might Give Impetus
May 23, 2017
- “Authorized Biosimilars” Could Be Priced at 50% of Originators: Prof.
May 23, 2017
- JDS, JGS Publish 1st Guideline for Treatment of Diabetes in the Elderly
May 22, 2017
- PI/II Study Suggests Efficacy of Eisai’s Anti-Fractalkine Antibody for RA
April 25, 2017
- Gastric Cancer Guidelines Likely to Recommend Opdivo in 3rd Line Settings
April 24, 2017
- Hepatology Society to Release Updated Hep C Guidelines Soon, Reflecting Ximency Use
March 3, 2017
- NCC to Begin IIT for Pediatric ALL with Velcade Plus 5 Drugs
February 23, 2017
- AMED Drafts Japan’s First Manual for Treatment of Mitochondrial Diseases
February 20, 2017
- PCSK9 Inhibitors More Effective than Statins at Lowering LDL-C: New Atherosclerosis Prevention Guidelines
January 31, 2017
- Zonisamide Investigator-Led Trial for Dementia Symptoms to Begin in April
January 27, 2017
- OB-GYN Society Again Nudges Govt to Reinstate HPV Vaccine Recommendation
January 19, 2017
- Reinstate HPV Vaccine Recommendation ASAP: OB-GYN Society
December 28, 2016
- NIBIOHN Bioinformatics Specialist Hopeful About Use of AI in Building Drug Discovery Support System
December 19, 2016
- New Lung Cancer Guidelines to Give Keytruda Grade A Recommendation as First-Line Treatment
December 19, 2016
- Need for Resistance Testing a Factor in Selection of IFN-Free Therapies for Hep C: Hepatologist
November 22, 2016
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…